First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 12, Pages e83232
Publisher
Public Library of Science (PLoS)
Online
2013-12-14
DOI
10.1371/journal.pone.0083232
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity
- (2013) Shane A. Olwill et al. MOLECULAR CANCER THERAPEUTICS
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡
- (2012) S. George et al. ANNALS OF ONCOLOGY
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients
- (2012) Esther Tahover et al. MEDICAL ONCOLOGY
- Tear Lipocalin: structure and Function
- (2012) Darlene A. Dartt Ocular Surface
- Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
- (2011) M. H. G. Langenberg et al. ANNALS OF ONCOLOGY
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Matrix metalloproteinases in tumorigenesis: an evolving paradigm
- (2011) Hui Hua et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker
- (2010) Emily S. Robinson et al. SEMINARS IN NEPHROLOGY
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypertension and proteinuria: a class-effect of antiangiogenic therapies
- (2008) Vincent Launay-Vacher et al. ANTI-CANCER DRUGS
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib
- (2008) T. V. Patel et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
- (2008) T. MEYER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now